MedTrace Logo

Pretargeted Radioimmunotherapy in Metastatic Colorectal Cancer

NCT02300922 · Status: TERMINATED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 7

Last updated 2022-08-01

No results posted yet for this study

Summary

Phase I/II, Open-labeled, Prospective, Multi-center study of a Pretargeted Radioimmunotherapy in metastatic colorectal cancer with ractionated injections of TF2 plus 90Y-IMP288 (RITCOLON).

Conditions

Interventions

DRUG

Antibody TF2

injection of a recombinant antibody CEA specific. Three injections. Each injection are separate by one week

DRUG

90-Y-IMP-288

Injection of the peptide 90-Y-IMP-288, 24 Hours after injection of TF2. 2 injections by patients separated by one week (week 2 and week 3)

DRUG

111-In-IMP-288

Injection of the peptide 111-In-IMP-288, 24 Hours after the first injection of TF2 (week 1)

Sponsors & Collaborators

  • Nantes University Hospital

    lead OTHER

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-01-27
Primary Completion
2017-09-20
Completion
2017-12-20

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02300922 on ClinicalTrials.gov